Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

摘要: Purpose: EGF receptor (EGFR) and HER2 positivity are considered to be negative prognostic factors in gastric cancer. Biomarker analysis was conducted evaluate the impact of EGFR expression on outcome patients enrolled Adjuvant Chemotherapy Trial TS-1 for Gastric Cancer (ACTS-GC), a randomized controlled trial comparing postoperative adjuvant S-1 therapy with surgery alone 1,059 stage II/III Experimental Design: Formalin-fixed, paraffin-embedded surgical specimens were retrospectively examined 829 (78.3%). The effects survival analyzed basis 5-year data from study. defined as an immunohistochemistry (IHC) score 3+, IHC 3+ or 2+ positive dual-color situ hybridization status. Results: 75 (9.0%) 113 (13.6%) patients, respectively. overall relapse-free rates significantly lower EGFR-positive than EGFR-negative whereas they similar HER2-positive HER2-negative patients. Multivariate showed that correlated poor outcomes [HR = 1.504; 95% confidence interval (CI) 1.020–2.149; P 0.040]. Treatment improved compared alone, irrespective Conclusions: positivity, but not associated patient after curative resection There no interaction between status respect outcome. Clin Res; 18(21); 5992–6000. ©2012 AACR .